Tenax Therapeutics reports $118M cash and Q2 2026 financial results.
Company reported $12.9M in R&D and $5.9M in SG&A, with net loss of $17.8M. Aiming for topline phase 3 data in August and full enrollment of LEVEL-2 by end-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day